Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Proteostasis

- PMLiVE

Results for Astellas’ non-hormonal menopause drug published in The Lancet

Symptoms such as hot flashes and night sweats are the most common symptoms of menopause

- PMLiVE

Astellas to support development of Taysha’s AAV-based gene therapy programmes

The company will receive an exclusive option to license two clinical stage programmes

- PMLiVE

Audentes’ rare disease gene therapy programme delayed after third patient death

Third patient death caused by gastrointestinal bleeding

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Hopes to extend the antibody drug conjugate's use into the earlier setting

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

- PMLiVE

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Closely follows $3bn acquistion of gene therapy specialist Audentes

- PMLiVE

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Plans to expand use into earlier bladder cancer treatment

- PMLiVE

Astellas makes gene therapy a core focus with $3bn Audentes buy

Deal includes a late-stage candidate for a rare disease

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links